Identification of a novel class of anti-Burkholderia compounds is key in 25 addressing antimicrobial resistance to current therapies as well as naturally 26 occurring resistance. The FabI enoyl-ACP reductase in Burkholderia is an 27 underexploited target that presents an opportunity for development of a new 28 class of inhibitors. A library of substituted diphenyl ethers were used to identify 29 fabI1 specific inhibitors for assessment in B. pseudomallei ex vivo and murine 30 efficacy models. Active FabI1 inhibitors were identified in a two-stage format 31 consisting of percent inhibition screening and minimum inhibitory concentration 32 (MIC) determination by microbroth dilution method. Each compound was 33 evaluated against the B. pseudomallei 1026b (efflux-proficient) and Bp400 34 (efflux-compromised) strains. In vitro screening identified candidate substituted 35 diphenyl ethers that exhibited MIC less than 1μg/ml and enzyme kinetic assays 36 were used to assess potency and specificity against FabI1 enzyme. These 37 compounds demonstrated activity in a Burkholderia ex vivo efficacy model and 38 two demonstrated efficacy in an acute B. pseudomallei mouse infection model. 39
INTRODUCTION 44
Burkholderia pseudomallei is a gram-negative bacteria endemic to Southeast 45 Asia and Northern Australia and is the causative agent of melioidosis. This 46 disease is difficult to manage and often fatal in humans if not aggressively and 47 the presence of a fixed concentration of DMSO (2% v/v) , NAD + (20-400 µM), 102 NADH (250 µM) and inhibitors (0-2000 nM) for 5 h at 4°C. After warming to 103 25°C, assays were initiated by the addition of Oct-CoA (30 µM). The inhibition 104 constant was calculated as previously described (18 Science, Gibbstown, NJ). Bacteria were added to 2.5x10 5 RAW cells per well in 155 a 24-well tissue culture plate at a multiplicity of infection of 5 CFU per cell in a 0.5 156 mL media. The plates were then centrifuged at 2,400 X g for 2 min and placed at 157
37
o C/5% CO 2 to incubate for 1 h. Supernatant was then removed; plate washed 158 once with 2 mL PBS and 1 mL of either 0.35 mg/mL kanamycin (Sigma-Aldrich, 159
St. Louis, MO) for wild-type strains or 0.1 mg/mL kanamycin (Sigma-Aldrich) for 160 double efflux mutant strains in complete media. Plates were then incubated for 1 161 h and washed 2 times with 2 mL PBS. 162
Selected compounds were then added to each well at either 10, 1, 0.1 163 μg/mL in complete media in triplicate. Untreated, 1 μg/mL doxycycline (Sigma-164 Aldrich), and 10 μg/mL ceftazidime were included as controls. Plates were 165 incubated for 18 h and cells observed for signs of infection. Cells were washed 3 166 times with 2 mL PBS and 1 mL sterile ddH 2 O added to each well. Each well was 167 thoroughly mixed/scraped to insure complete cell lysis. Lysates were then 168 Bp400 mutant strain and efflux-proficient strain B. pseudomallei 1026b. PT52, 213 PT55, and PT68 had MIC values less than 1 μg/mL against B. pseudomallei 214 Bp400 (Table 1) . Evaluation of PT51, PT52, PT55, and PT68 against the efflux-215 proficient strain B. pseudomallei 1026b resulted in increased MIC values due to 216 drug efflux (Table 1) . While the majority of substituted diphenyl ethers 217 demonstrated potency against Burkholderia, they were also readily effluxed. 218 on July 9, 2017 by guest http://aac.asm.org/
Downloaded from
The cytotoxicicty of each compound was evaluated using a standard Vero 219 cell assay (Table 1) . Each diphenyl ether compound exhibited LD 50 values 100-220 fold greater than MIC, which is consistent with our previous reports for 221 compounds in this drug series (20). There was no toxicity observed in the ex 222 vivo RAW264.7 macrophage assay for the clinical drugs ceftazidime and 223 doxycline, which is consistent with published reports (23). (Table 3) whole bacteria activity and in vivo efficacy against F. tularensis Schu4 (13, 14) . 290
In this study we have shown this same class of compounds to be 291 efficacious for in vitro and ex vivo activity against efflux-compromised B. 292 pseudomallei Bp400. Unfortunately, the majority of compounds in this class are 293 efflux pump substrates, and while they are effluxed similar to existing clinically 294 used drugs to treat melioidosis, for instance doxycycline, modifications to existing 295 compounds will be made to address this issue or current compounds will need to 296 be formulated to deliver the higher dose requirement that exceeds the higher 297
MIC value. 298
Importantly, PT52 and PT68 were shown to significantly reduce bacterial 299 burden in the spleen and only PT52 significantly reduced bacterial burden in the 300 lung when compared to untreated mice. This observation, along with the ability 301 of these compounds to display a low nanomolar binding affinity to FabI1 in vitro, 302 suggests that the use of substituted diphenyl ethers to inhibit FabI1 enoyl-ACP 303 reductase in Burkholderia can be exploited to control infection. Steady-state 304 kinetic analysis showed that PT52 and PT68 were promising inhibitors due to 305 favorable optimization of thermodynamic parameters, specifically inhibitor binding 306 to the FabI1-NAD + complex represented by K 1 . This final stable ground state was 307 coupled with a slow-onset inhibitor mechanism, which was lacking in compounds 308 on July 9, 2017 by guest
